Main Menu

Spring 2017

From the Director

Dear Readers, Quality of life for patients is a top priority at the Myeloma Institute.  Our team is committed to providing a comprehensive, holistic experience, including effective disease management and emotional support for patients, family members and caregivers. We believe that patients should be able to live their lives as fully as possible with minimal [...]

July 27th, 2017|Spring 2017|

Bone Disease in Myeloma

Donghoon Yoon, Ph.D., in his lab where his focus is on the factors and mechanisms of bone metabolism in myeloma Bone disease is a hallmark of myeloma, affecting up to 90 percent of patients. An unexplained fracture or bone pain can be the first sign that something is not right and often leads patients to [...]

July 27th, 2017|Spring 2017|

Bone Remodeling Clinical Trial Assessment

Carolina Schinke, M.D., assistant professor, conducts research that leads to development of new clinical trials. Bone disease is a major issue for the majority of multiple myeloma patients.  Lytic lesions, fractures and collapse of vertebra in the spine — primary causes of pain and debilitation — can significantly compromise quality of life. Clinical treatment for [...]

July 27th, 2017|Spring 2017|

Partners in Care

Bobbie Rainey receiving a post-surgery exam by orthopaedic surgeon Corey Montgomery, M.D. Bobbie Rainey from Gould, Arkansas, came to the Myeloma Institute in September of 2010.  She was experiencing pain all over her body, especially her lower back, legs and arms, in addition to other symptoms of myeloma. Due to a persistent bone lesion in [...]

July 27th, 2017|Myeloma Magazine, Spring 2017|

Plasma Cell Neoplasm — A Brief Primer

While multiple myeloma is the primary disease treated at the Myeloma Institute, other plasma cell neoplasms are also the focus of our research and treatment regimens. What is a Plasma Cell Neoplasm? A neoplasm is an abnormal mass of tissue that results when cells divide more than they should or do not die when they [...]

July 27th, 2017|Myeloma Magazine, Spring 2017|

publications

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker A new publication in Blood Cancer Journal 24 February 2017, PMID: 28234347 Primary Authors: Shweta Chavan, Ph.D., and Brian Walker, Ph.D. Targeted gene sequencing was conducted on 578 cases of plasma cell neoplasms, including monoclonal gammopathy of undermined [...]

July 27th, 2017|Myeloma Magazine, Spring 2017|

Giving Back and Creating a Legacy

The Myeloma Institute is a trailblazer in the development of innovative treatments for myeloma and other plasma cell neoplasms. With a firm commitment to helping patients regain their lives and look forward to a disease-free future, the institute’s health care team provides expertise while extending compassion and encouragement. Patients and families frequently ask how they [...]

July 27th, 2017|Myeloma Magazine, Spring 2017|

Exceeding Expectations

Ambassador Ruth A. Davis traveled the world as a diplomat during her 40 years with the U.S. Foreign Service. But when she learned she had a relapse of multiple myeloma, she headed to Arkansas and the UAMS Myeloma Institute. “I’ve often had people ask me, ‘Why don’t you go somewhere in the area, closer to [...]

July 27th, 2017|Myeloma Magazine, Spring 2017|

Finding the Way

How do new patients find their way to the Myeloma Institute? Often through a family physician or local oncologist or through a lot of online research. Sometimes the path is a bit circuitous. That was the case for Linda King from Lee’s Summit, Missouri. In 2006 Linda received the devastating news of her diagnosis, thanks [...]

July 27th, 2017|Myeloma Magazine, Spring 2017|